ADMA Biologics, Inc.
ADMA
$19.64
-$1.67-7.84%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 59.06% | 78.13% | 78.29% | 43.86% | 47.86% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 59.06% | 78.13% | 78.29% | 43.86% | 47.86% |
| Cost of Revenue | 33.15% | 41.19% | 14.52% | 5.86% | 13.72% |
| Gross Profit | 90.84% | 141.99% | 244.24% | 136.83% | 134.09% |
| SG&A Expenses | 58.47% | 28.88% | 12.64% | 2.16% | -18.24% |
| Depreciation & Amortization | -86.63% | -84.36% | -20.67% | 7.82% | 4.76% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 39.31% | 36.89% | 12.20% | 4.03% | 1.48% |
| Operating Income | 124.99% | 356.40% | 8,387.74% | 2,784.01% | 381.14% |
| Income Before Tax | 296.73% | 1,332.71% | 662.72% | 371.04% | -44.26% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 734.15% | 1,299.96% | 603.25% | 362.28% | -44.26% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 734.15% | 1,299.96% | 603.25% | 362.28% | -44.26% |
| EBIT | 124.99% | 356.40% | 8,387.74% | 2,784.01% | 381.14% |
| EBITDA | 110.36% | 285.80% | 2,438.34% | 1,861.89% | 564.39% |
| EPS Basic | 706.02% | 1,242.98% | 582.17% | 354.25% | -29.52% |
| Normalized Basic EPS | 203.51% | 1,278.87% | 638.55% | 362.83% | 183.02% |
| EPS Diluted | 676.07% | 1,400.00% | 533.33% | 354.25% | -30.59% |
| Normalized Diluted EPS | 192.01% | 1,259.42% | 616.76% | 354.45% | 183.02% |
| Average Basic Shares Outstanding | 4.63% | 4.13% | 4.37% | 3.13% | 11.41% |
| Average Diluted Shares Outstanding | 8.82% | 4.72% | 8.75% | 6.53% | 11.41% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |